Veradermics, Incorporated (MANE)
| Market Cap | 1.71B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -61.64M |
| Shares Out | 37.34M |
| EPS (ttm) | -83.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 279,377 |
| Open | 42.58 |
| Previous Close | 42.91 |
| Day's Range | 42.58 - 45.88 |
| 52-Week Range | 32.00 - 51.56 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About MANE
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for... [Read more]
Financial Performance
Financial StatementsNews
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 12, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the N...
Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for comm...
U.S. IPO Weekly Recap: 7 IPOs Make It One Of The Busiest Weeks In 4 Years
Seven IPOs and six SPACs priced this week. Five IPOs and five SPACs submitted filings. Five IPOs are currently scheduled in the week ahead, and some smaller issuers may join the calendar throughout th...
Veradermics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative thera...
Veradermics Announces Pricing of Upsized Initial Public Offering
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative thera...
Veradermics Finalizes $200 Million IPO Target
Veradermics is set to raise $200 million in an IPO to fund its novel extended-release oral minoxidil for pattern hair loss, addressing a $9B U.S. market.
Veradermics, Dermatology Biopharma Focused on Hair Loss, Files for NYSE IPO
Veradermics, a late-stage dermatology biopharma, filed an S-1 for an initial public offering...
Veradermics IPO Registration Document (S-1)
Veradermics has filed to go public with an IPO on the New York Stock Exchange (NYSE)
Hair loss biotech Veradermics files for a $100 million IPO
Veradermics, a Phase 3-ready biotech developing therapies for hair loss, filed on Friday with the SEC to raise up to $100 million in an initial public offering.